Remove Medicine Remove Pharmacology Remove Safety
article thumbnail

Gilead data lends insight into transforming HIV prevention landscape

European Pharmaceutical Review

New clinical trial findings show that twice-yearly lenacapavir for HIV pre-exposure prophylaxis (PrEP) had high efficacy and safety in a diverse group of participants. This data provides the first in-depth insight into full results of Gilead Sciences pivotal Phase III PURPOSE 2 trial.

article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

The Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), Dame June Raine, will step down in the Autumn following five years in the role. While she is stepping down from her current role, Dame June shared that she still hopes to contribute β€œto patient safety and public health in other ways.”

Safety 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

The FDA’s role in the regulation of botanical drug products includes an assessment of their safety and efficiency 5 but insufficient evidence for efficacy is one of the most common reasons why new drug candidates fail to reach this step. 6 Thus, it is critical to ensure the consistency of therapeutic effect across batches (see box).

Marketing 103
article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

Personalized Medicine AI can help develop precision medicine by analyzing patient data , including demographic, clinical, and genetic information, as well as information about their metabolism and microbes, environmental exposures, and lifestyle factors, to predict how different patients will respond to various therapies.

Pharma 95
article thumbnail

Why There's No Such Thing as a 'Safe' Drug?

Contrarian Sales Techniques

During my pharmacology class, I learned that there are no safe drugs, only safe patients. This highlights the importance of taking an individualized approach to medicine and considering a patient's unique medical history, current health status, and other relevant factors when prescribing medication.

article thumbnail

Developing new treatment regimens for HIV

European Pharmaceutical Review

HIV treatment and prevention are at an inflection point after years of continuously improving the standard of care of once-daily oral medicines. Our industry is on the cusp of the next wave of medicines that will guide the coming decade of HIV care, making HIV a smaller part of people’s lives. 3 But that paradigm is rapidly changing.

article thumbnail

Leading API biologics (protein and peptide) companies in contract marketing

Pharmaceutical Technology

Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development.

Leads 52